HOERSHOLM, Denmark -
- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma’s Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders
- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery
- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.
(Logo: www.newscom.com/cgi-bin/prnh/20090420/344344 )
The alliance will use Santaris Pharma A/S’ proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.
Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completion of certain initial studies. The initial term of the research collaboration is two years; Shire has an option to extend for up to two additional years.
“We are delighted that the increasing interest in the LNA Drug Platform and our Drug Discovery Engine so quickly has materialized in our fourth strategic alliance. The alliance with Shire demonstrates the broad utility of Santaris Pharma’s proprietary LNA Drug Platform for developing treatments for an extensive range of diseases, now also including rare genetic disorders,” said Søren Tulstrup, President and CEO of Santaris Pharma A/S. “This fourth partnership follows only seven months after the announcement of our new strategic alliance with Wyeth Pharmaceuticals and further demonstrates our leading position in the rapidly evolving RNA-based therapeutics field.”
In addition to these initial payments Santaris Pharma A/S will receive funding for all additional discovery activities to be performed under the contract, payments on Shire’s nomination of up to two additional targets, and will be eligible to receive development, regulatory and sales related milestone payments of up to US$72 million for each of the potential five drug candidates and customary royalties on the worldwide sales of commercialized products arising from the alliance.
“We are excited to be collaborating with Santaris Pharma A/S, a leader in the field of RNA-based therapeutics. Its LNA technology and experienced management team are a good fit for Shire,” said Dr. Whaijen Soo, Senior Vice President, Research and Development, Shire Human Genetic Therapies. “We look forward to working closely with the Santaris Pharma A/S team and expanding our pipeline by discovering and developing new RNA-based medicines to treat rare genetic disorders.”
Santaris Pharma A/S’ worldwide strategic alliance with Shire to discover and develop new medicines targeting rare genetic disorders adds to the growing list of mRNA and microRNA drug discovery and development partnerships that include Wyeth (delivery of lead candidates against up to ten mRNA and microRNA targets), GlaxoSmithKline (four viral disease drug candidates) and Enzon Pharmaceuticals (eight cancer targets successfully delivered).
About Locked Nucleic Acid (LNA) Drug Platform
The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetic chemical versions called LNAs of the normal nucleic acid building blocks of ribonucleic acids (RNA). These LNAs improve the drug-like qualities of resulting therapeutics, called oligonucleotides, by boosting resistance to metabolism, increasing half-life and improving tissue uptake. LNA-based therapeutics demonstrate improved binding affinity to their target RNA, which increases potency many-fold over other nucleotide therapeutics. The greater potency of LNA in binding complementary RNA sequences also allows for the use of significantly shorter LNA oligonucleotide drugs which can be more effective than previous antisense or siRNA drugs.
About Santaris Pharma A/S
Santaris Pharma A/S is a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs. Utilizing the Company’s proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S provides fast and efficient generation of lead LNA drug candidates. The Company’s own research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the US. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals and Shire plc. Please visit www.santaris.com for more information.
Source: Santaris Pharma A/S
Media Contacts: Randi Krogsgaard, Santaris Pharma A/S, Kogle Allé 6, DK - 2970 Hoersholm, Direct phone: +45-45179879, Cell: +45-20488384, Email: rmk at santaris.com; Navjot Rai, Santaris Pharma A/S, Kogle Allé 6, DK - 2970 Hoersholm, Direct phone: +1-619-723-5450, Cell: +1-619-723-5450, Email: nra at santaris.com
Related Press Releases
New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US OperationsSeptember 15th, 2009 HOERSHOLM, Denmark and SAN DIEGO, California -
- Denmark-Based Santaris Pharma A/S Appoints Leading RNA Industry Expert Art Levin Ph.D. as President of US Operations and Chief Development Officer
- Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid (LNA) -and Drug Discovery Engine, the US Subsidiary Aims to Foster Relationships With New Partners, Increase Visibility With Capital Markets and Attract Leading Scientists
- Santaris Pharma A/S is First Company to Advance a microRNA-Targeted Drug into Human Clinical Trials; SPC3649 Targets miR-122 for the Treatment of Hepatitis C
- Recently Announced Strategic Alliance With Shire Demonstrates LNA is Rapidly Becoming the Chemistry-of-Choice and Adds to the Growing List of mRNA and microRNA Drug Discovery and Development Partnerships That Include Wyeth, GlaxoSmithKline and Enzon for a Range of Diseases
Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States.
Update on Velaglucerase AlfaSeptember 7th, 2009 CAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide.
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug PlatformAugust 23rd, 2009 CAMBRIDGE, Massachusetts -
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.
Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher DiseaseJuly 5th, 2009 LEXINGTON, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher Disease. If approved by the FDA, the treatment protocol would allow physicians to treat Gaucher Disease patients with velaglucerase alfa ahead of commercial availability in the US.
Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009April 19th, 2009 DUBLIN, Ireland - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce first quarter 2009 earnings on Thursday April 30, 2009. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:30 BST / 09:30 EDT
Live conference call for investors:
Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:30 BST/9:30 EDT.
Dutch Consortium Builds Registry Framework for Care of Rare DiseasesApril 5th, 2009 LEIDEN, The Netherlands - The Dutch Orphan Disease Registry Consortium is set up in order to build a disease registry framework to collect information on rare diseases, encourage drug development and optimize patient care. The consortium focuses on inborn errors of metabolism as target group of diseases.
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) PatentsApril 1st, 2009 PHILADELPHIA - Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Natco Pharma Limited ("Natco") for infringement of two of Shire's patents: U.S.
Another LNA-based RNA Inhibitor Enters Clinical TrialsMarch 19th, 2009 COPENHAGEN - EZN3042 - a Survivin Inhibitor Jointly Developed by Enzon
Pharmaceuticals and Santaris Pharma Advances into the Clinic for Patients
With Solid Tumors and Lymphomas
Santaris Pharma announced today that the fourth LNA-based drug
has been brought into the clinic. In the USA several patients with cancer
have now been treated with the Company's Survivin inhibitor, which is jointly
developed by Santaris Pharma and Enzon Pharmaceuticals.
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) PatentMarch 19th, 2009 PHILADELPHIA, Pennsylvania and DUBLIN, Ireland - Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit
in the U.S. District Court of the Southern District of New York against Mylan
Inc., Mylan Pharmaceuticals Inc.
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) PatentsMarch 15th, 2009 PHILADELPHIA, Pennsylvania and DUBLIN, Ireland - Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has
filed a lawsuit in the U.S. District Court of the Southern District of New
York against Barr Laboratories, Inc.
Related News
Interplay of maternal, paternal genes may last well into childhoodJuly 29th, 2009 WASHINGTON - The subtle tug-of-war between maternal and paternal genes is likely to track into childhood, and possibly as late as the onset of puberty, say researchers. Human development is set by ongoing interplay of parent and offspring genes.
Circulating blood cells can form bone outside the normal skeletonJuly 24th, 2009 WASHINGTON - Circulating cells in the blood have the ability to form bone at sites distant from the original skeleton, according to a new research. It is believed that bone-forming cells, derived from the body's connective tissue, are the only cells able to form the skeleton.
Ghaziabad police bust fake medicine racketMay 26th, 2009 GHAZIABAD - The Ghaziabad police Tuesday claimed to have busted a racket in counterfeit medicines of internationally renowned prestigious brands. A huge cache of fake medicines worth at least Rs.five million was recovered in the raid.
Eating disorders can have dire effects on body, mindMarch 18th, 2009 LONDON - Eating disorders have dire consequences, physically, psychologically and socially, and there are disorders that are even more widespread in their effects. Much research has been undertaken in order to find out the factors involved in their development, but the role played by the various emotional variables at the onset of these disorders has hardly been investigated.
New 'biofactories' produce rare healing substances in endangered Devil's claw plantAugust 17th, 2009 WASHINGTON - A group of scientists has reported the development of new 'biofactories' which can produce rare healing substances in the endangered Devil's claw plant. The Devil's claw plant, which lies in Africa's Kalahari Desert, hold the key to effective treatments for arthritis, tendonitis and other illnesses that affect millions each year.
New type of botulinum may smoothen wrinkled foreheadMarch 17th, 2009 WASHINGTON - A new type of botulinum toxin may smoothen moderate to severe forehead wrinkles, according to a new study. Injecting low doses of Clostridium botulinum toxin type A (Reloxin) is a method in vogue for treating lines on the face.
Essential CRO, Ecron Acunova form global allianceJuly 31st, 2009 BANGALORE - Two leading full service contract research organizations (CRO's), Essential CRO and Ecron Acunova today announced the formation of a global strategic alliance to strengthen the service offerings in emerging markets and help customers leverage the convergence of a broad global network. This alliance provides pharmaceutical, biotechnology, device, diagnostic and nutritional sponsors with access to 18 countries in key emerging sectors for clinical research.
Maxygen CEO and CFO to leave Wednesday as part of expanded partnership with Astellas PharmaSeptember 30th, 2009 Maxygen says CEO and CFO will leave Sept. 30NEW YORK — Maxygen Inc.
Mining company questions whether Wyo. panel can label federal forest land 'rare and uncommon'July 17th, 2009 Wyoming Black Hills petition raises legal issueCHEYENNE, Wyo. — A request that a Wyoming panel designate a piece of the Black Hills National Forest as "very rare and uncommon" has raised questions about the state's authority to influence what happens on federal land.
GlaxoSmithKline posts 13 percent drop in 1Q net profit as US pharma business slumpsApril 22nd, 2009 Glaxo 1Q profit drops 13 percentLONDON — GlaxoSmithKline, the world's second largest drug maker by revenues, posted a 13 percent drop in net profit for the first quarter on Wednesday, as strong sales in Europe and emerging markets were offset by a poor performance in its U.S. pharmaceutical business.
